A peptide antagonist of α3β2-subunit containing and α7 nAChRs
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

α-Conotoxin PnIA (trifluoroacetate salt)

Item No. 36197

Technical Information
Formal Name
glycyl-L-cysteinyl-L-cysteinyl-L-seryl-L-leucyl-L-prolyl-L-prolyl-L-cysteinyl-L-alanyl-L-alanyl-L-asparaginyl-L-asparaginyl-L-prolyl-L-α-aspartyl-L-tyrosyl-L-cysteinamide, cyclic (2→8), (3→16)-bis(disulfide), trifluoroacetate salt
Synonyms
  • α-CtxPnIA
  • αPnIA
Molecular Formula
C65H95N19O22S4 • XCF3COOH
Formula Weight
Purity
≥95%
A solid
Water: soluble
SMILES
OC(C[C@H](NC([C@@H]1CCCN1C([C@H](CC(N)=O)NC([C@H](CC(N)=O)NC([C@@H](NC([C@@H](NC([C@H](CSSC2)NC([C@@H]3CCCN3C([C@@H]4CCCN4C([C@@H](NC([C@H](CO)NC([C@H]5NC([C@H]2NC(CN[H])=O)=O)=O)=O)CC(C)C)=O)=O)=O)=O)C)=O)C)=O)=O)=O)=O)C(N[C@@H](CC(C=C6)=CC=C6O)C(N[C@@H](CSSC5)C(N)=O)=O)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C65H95N19O22S4.C2HF3O2/c1-29(2)18-37-63(104)84-17-7-10-46(84)65(106)83-16-6-9-45(83)62(103)81-42-27-110-108-26-41(72-49(89)23-66)59(100)80-43(60(101)78-39(24-85)57(98)76-37)28-109-107-25-40(51(69)92)79-54(95)34(19-32-11-13-33(86)14-12-32)74-56(97)36(22-50(90)91)75-61(102)44-8-5-15-82(44)64(105)38(21-48(68)88)77-55(96)35(20-47(67)87)73-53(94)31(4)70-52(93)30(3)71-58(42)99;3-2(4,5)1(6)7/h11-14,29-31,34-46,85-86H,5-10,15-28,66H2,1-4H3,(H2,67,87)(H2,68,88)(H2,69,92)(H,70,93)(H,71,99)(H,72,89)(H,73,94)(H,74,97)(H,75,102)(H,76,98)(H,77,96)(H,78,101)(H,79,95)(H,80,100)(H,81,103)(H,90,91);(H,6,7)/t30-,31-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-;/m0./s1
InChi Key
GOKZDANAEFVABE-SIOUEYJBSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Environmental Toxicology Resource Center

    Explore additional resources to study natural toxins, pollutants including PFAS and 6-PPD-Q, and their biological effects.

    ENVIRONMENTAL TOXICOLOGY TOOLS & SERVICES
    Product Description

    α-Conotoxin PnIA is a peptide originally isolated from the venom of the marine mollusk C. pennaceus and an antagonist of α3β2 subunit-containing nicotinic acetylcholine receptors (nAChRs) and α7 nAChRs (IC50s = 7.9 and 62.7 nM, respectively).1,2 α-Conotoxin PnIA (0.1 nmol/kg) in combination with baicalein (Item No. 70610) inhibits tumor growth and increases survival in an Ehrlich murine spontaneous adenocarcinoma model.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Fainzilber, M., Hasson, A., Oren, R., et alNew mollusc-specific α-conotoxins block Aplysia neuronal acetylcholine receptors. Biochemistry 33(32), 9523-9529 (1994).

    2. Hopping, G., A., W.C.-I., Hogg, R.C., et alHydrophobic residues at position 10 of α-conotoxin PnIA influence subtype selectivity between α7 and α3β2 neuronal nicotinic acetylcholine receptors. Biochem. Pharmacol. 91(4), 534-542 (2014).

    3. Osipov, A.V., Terpinskaya, T.I., Yanchanka, T., et alα-Conotoxins enhance both the in vivo suppression of Ehrlich carcinoma growth and in vitro reduction in cell viability elicited by cyclooxygenase and lipoxygenase inhibitors. Mar. Drugs 18(4), 193 (2020).